Update on EGFR Mutational Testing and the Potential of Noninvasive Liquid Biopsy in Non–Small-cell Lung Cancer

摘要: Mutations in the epidermal growth factor receptor (EGFR) are important drivers of non-small-cell lung cancer (NSCLC) and have led to emergence EGFR-targeted therapies as critical treatment options for NSCLC. Although these agents shown clinical activity NSCLC patients, acquired resistance is inevitable. Therefore, ability conveniently biopsy patient tumors increasing importance new mechanisms target mutations identified. Rapid accurate EGFR mutational testing specimens, including liquid allows identification potentially actionable that could guide treatment. In present review, we discuss various methods best practices tumor sampling